Valens GroWorks Corp (CSE:VGW,OTC:MYMSF) released its eleventh episode on its Extraction podcast this week during which they talked to Stoic Advisory Founder and thought leader Aaron Salz. Salz provided his thoughts on what’s next in the cannabis industry and how to properly evaluate companies. Stoic Advisory is a Toronto-based corporate advisory firm focused on the global cannabis industry. It doesn’t provide stock tips to investors but offers merger and acquisition services. However, Salz feels a personal responsibility to help investors set realistic expectations when entering the market.

Salz’s number one suggestion to investors is to do their due diligence. He stated that Stoic Advisory looks at the jurisdiction and the overall company before moving ahead with a transaction. In more advanced jurisdictions like Canada, his firm looks at the company’s capital structure and management team. He also recommended having a diverse portfolio that primarily consists of large cap, blue chip names and not to make decisions based on the fear of missing out (FOMO).

“It’s really just FOMO. FOMO drives so much in this space from an investment standpoint, from the retail level up to the institutional level. It’s the worst reason to invest in things,” said Salz.

Salz also pointed out that the recreational market in Canada hasn’t performed as expected. He believes this is due to missing product offerings, such as edibles and extracts. Salz pointed out that edibles, extracts and vapes make up to 60 percent of sales in some US states. Salz is the most interested in the vape market and is wary of the beverage market due to the “high-stakes” that large beverage companies brought to the table.

To listen to the podcast, click here.

Click here to connect with Valens GroWorks Corp (CSE:VGW, OTC:MYMSF) for an Investor Presentation.


Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less